Company Long-Term Loans and Borrowings: Pieris (PIRS)

Public company logo of Pieris (PIRS)

The daily price chart reflecting the value of Pieris Pharmaceuticals (PIRS) long-term liabilities relies on the neutral geopolitical status of medicine, which shields the company's scientific ties from sanctions. Operational flexibility is achieved through a German R&D center and US-based contract manufacturing. Revenues are based on royalties and upfront payments from global behemoths for the development of protein drugs, with the metric standing at 0.02.

PIRS Pieris Pharmaceuticals Company Long-Term Debts (07/04/2022 - 10/30/2026)

Summary analytical data breakdowns for Pieris (PIRS)

- market price and analyst price targets:
Stock Price pieris.com|PIRS - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Pieris Pharmaceuticals|PIRS - Total Company Value
- book capitalization information:
Accounting Value per Share Pieris Pharmaceuticals|PIRS - Book Capitalization|Market Capitalization to Book Value Ratio pieris.com|PIRS - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Pieris Pharmaceuticals|PIRS - Long-Term Debt to Equity|Current Liabilities to Capital Pieris Pharma|PIRS - Company Total Debt|Debt to Book Capital Pieris Pharmaceuticals|PIRS - Company Long-Term Debts|Company Short-Term Loans and Borrowings Pieris Pharmaceuticals|Immediate Liquidity pieris.com
- earnings and multiples data:
PIRS - Company Net Income
Fundamental company valuation:pieris.com PIRS
Brand item of Pieris Pharmaceuticals, Inc.

Long-term liabilities determine the financial stability and ability of Pieris Pharmaceuticals (PIRS) to service borrowed capital over a horizon exceeding one year. This metric measures the volume of external financing critical for capital-intensive R&D projects. Assessing the long-term debt of Pieris Pharmaceuticals (PIRS) allows for tracking the borrowing pace used to develop the Anticalin platform and the PRS-220 drug. The stability of this line confirms balanced liquidity management while awaiting partner payments. Monitoring this indicator minimizes bankruptcy risks in the event of clinical trial stagnation.

Who Pieris Pharmaceuticals competes with

Company Long-Term Debts haleon.com HLN|KVUE - Company Long-Term Debt|Company Long-Term Loans and Borrowings VRNA (Verona Pharma PLC)|Jyong Biotech Corp (MENS) - Company Long-Term Debt|Company Long-Term Liabilities Ligand Corp|AMRX (Amneal Pharmaceuticals) - Company Long-Term Debts|Company Long-Term Debts perrigo.com|Company Long-Term Liabilities ALVO (Alvotech SA)|LQDA (Liquidia Corp) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Galapagos Genomics GLPG|ANI Pharmaceuticals Corp (ANIP) - Long-Term Debt|MNKD: Company Long-Term Liabilities|amphastar.com - Amount of Long-Term Liabilities|PCRX: Company Long-Term Debts|ARS Pharmaceuticals Inc - Company Long-Term Loans and Borrowings|TBPH (Theravance) - Company Long-Term Debts|Long-Term Debt Aquestive Corp AQST|Company Long-Term Debt scPharmaceuticals Inc. (SCPH)|TECX (tectonictx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Tonix Pharmaceuticals Holding Corp. TNXP|SXTC (SXT Pharmaceuticals) - Long-Term Liabilities|Eupraxia Pharma - Company Long-Term Debts|Long-Term Debt Volume BioHarvest Sciences Inc BHST|EXOZ: Company Long-Term Debts|Long-Term Debt Oramed Pharmaceuticals Inc. (ORMP)|Company Long-Term Debt Entera Bio Ltd|HYFT: Company Long-Term Loans and Borrowings|Company Long-Term Debts ABVC|Long-Term Debt Volume Cumberland Corp|Company Long-Term Debt Quantum BioPharma Ltd QNTM|Long-Term Debt Volume fibrogen.com (FGEN)|TELO: Company Long-Term Liabilities|Company Long-Term Loans and Borrowings RANI (Rani Therapeutics)|synergychc.com (SNYR) - Company Long-Term Debt|Long-Term Liabilities RLYB (Rallybio)|LEXX (Lexaria Bioscience Corp) - Company Long-Term Debts|PULM: Company Long-Term Loans and Borrowings|Company Long-Term Debts PTHL|Company Long-Term Debts aptorumgroup.com (APM)|Company Long-Term Debt Lyra Therapeutics, Inc LYRA|Company Long-Term Loans and Borrowings IBO|TNFA - Company Long-Term Debt|cbdMD, Inc. (YCBD) - Company Long-Term Liabilities|PRFX: Company Long-Term Debts|Altamira Therapeutics Ltd. (CYTO) - Company Long-Term Debts|LIPO (Lipella) - Company Long-Term Debts|Company Long-Term Liabilities OptiNose Corp (OPTN)|Company Long-Term Debts PROC|PTPI - Long-Term Debt|Qilian International Holding - Company Long-Term Liabilities|Company Long-Term Debts Acelyrin Inc. SLRN|TFFP: Company Long-Term Liabilities